EDMONTON, Aug. 5 /CNW/ - Valens Pharma Ltd. (Valens, formerly known as "CardioMetabolics Inc."), today announced that the Company has suspended work on its DCA i.v program, a proprietary intravenous formulation of dichloroacetate pending further... Discuss Add this link to... Tell a friendBury Add to:
">
| Bookmarks
Comments